“Rivaroxaban versus Warfarin for Prevention of Thromboembolism in Bangladeshi Patients with Non-Valvular Atrial Fibrillation”, Univ. Heart J., vol. 16, no. 2, pp. 99–105, Oct. 2020, doi: 10.3329/uhj.v16i2.49666.